Variants of traf2 which act as an inhibitor of tnf-alpha (tnf .alpha.) signaling pathway
CA 2372803 A1 · Owner: Clark, Kenneth L. · Inventors: Searfoss, George H. Iii; Guo, Kun; Ivashchenko, Yuri D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to variants of TRAF2 which demonstrate the ability to inhibit the TNF .alpha. signaling pathway. In particular applicants have isolated a splice variant of TRAF2 referred to hereinafter as "TRAF2 truncated" or "TRAF2TR" and a TRAF2 expression construct with enhanced dominant negative properties, hereafter referred to as "TRAF2 truncateddeleted" or "TRAF2TD". Both TRAF2TR and TRAF2TD have the ability to inhibit the TNF .alpha. signaling pathway and in TRAF2TD this ability is greatly , enhanced, greatly reducing the response to TNF .alpha. binding.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 6, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.